Status:
COMPLETED
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
Lead Sponsor:
AstraZeneca
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-100 years
Brief Summary
To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.
Detailed Description
Plaque psoriasis is a chronic skin disease affecting 1-3% of US and European populations and severely impairs quality of life. Four biologics are authorized in Europe and the US for treatment of patie...
Eligibility Criteria
Inclusion
- subjects who are greater than or equal to 18 YO diagnosed with moderate to severe plaque psoriasis
- subjects who will be initiating therapy with a biologic approved for moderate to severe psoriasis either for the first time (biologic treatment naive) or in course of switching to a different biologic agent
- subject who is able to complete questionnaires
- subject able to provide written informed consent
Exclusion
- \- subjects who are participating in a clinical trial utilizing an investigational agent in the 3 months prior to the first biologic dose on study
Key Trial Info
Start Date :
March 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 5 2017
Estimated Enrollment :
899 Patients enrolled
Trial Details
Trial ID
NCT02239666
Start Date
March 1 2014
End Date
January 5 2017
Last Update
August 3 2017
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States, 35233
2
Research Site
Hot Springs, Arkansas, United States, 71913
3
Research Site
Rogers, Arkansas, United States, 72758
4
Research Site
Bakersfield, California, United States, 93309